Human-specific regulatory features of brain development manifest staggering breadth of associations with physiological processes and pathological conditions of *H. sapiens*

Gennadi V. Glinsky[1]

[1] Institute of Engineering in Medicine

University of California, San Diego

9500 Gilman Dr. MC 0435

La Jolla, CA 92093-0435, USA

Correspondence: gglinskii@ucsd.edu

Web: http://iem.ucsd.edu/people/profiles/guennadi-v-glinskii.html

Running title: Human-specific regulatory control of 2,273 offspring survival genes

Key words: human phenotypic uniqueness; human-specific regulatory sequences; human-specific traits; human-specific single nucleotide changes.

Abstract

In recent years, elucidation of genetic and molecular mechanisms defining the phenotypic uniqueness of Modern Humans attained a significant progress in illuminating the essential role of human-specific regulatory sequences (HSRS). The macromolecules comprising the essential building blocks of life at the cellular and organismal levels remain highly conserved during the evolution of humans and other Great Apes. Identification of nearly hundred thousand candidate HSRS validate the idea that unique to human phenotypes may result from human-specific changes to genomic regulatory sequences defined as “regulatory mutations” (King and Wilson, 1975). The exquisite degree of accuracy of the state-of-art molecular definition of HSRS is illustrated by identification of 35,074 single nucleotide changes (SNCs) that are fixed in humans, distinct from other primates, and located in differentially-accessible (DA) chromatin regions during the human brain development (Kanton et al., 2019). Annotation of SNCs derived and fixed in modern humans that overlap DA chromatin regions during brain development revealed that 99.8% of candidate regulatory SNCs are shared with the archaic humans. This remarkable conservation on the human lineage of candidate regulatory SNCs associated with early stages of human brain development suggest that coding genes expression of which is regulated by human-specific SNCs may have a broad effect on human-specific traits beyond embryonic development. Gene set enrichment analyses of 8,405 genes linked with 35,074 human-specific SNCs revealed the staggering breadth of significant associations with morphological structures, physiological processes, and pathological conditions of Modern Humans, including more than 1,000 anatomically-distinct regions of the adult human brain, many types of human cells and tissues, more than 200 common human disorders and more than 1,000 rare diseases. Thousands of genes connected with human-specific regulatory SNCs represent essential genetic elements of the autosomal inheritance and survival of species phenotypes: a total of 1,494 genes linked with either autosomal dominant or recessive inheritance as well as 2,273 genes associated with premature death, embryonic survival, and perinatal, neonatal, and postnatal lethality of both complete and incomplete penetrance have been identified in this contribution. Therefore, thousands of heritable traits and critical genes impacting the offspring survival appear placed under the human-specific regulatory control in genomes of Modern Humans. These observations highlight the remarkable translational opportunities with

clinical utility potentials afforded by the discovery of genetic regulatory loci harboring human-specific SNCs in the ground-breaking fundamental study of great ape's cerebral organoids.

Introduction

DNA sequences of coding genes defining the structure of macromolecules comprising the essential building blocks of life at the cellular and organismal levels remain highly conserved during the evolution of humans and other Great Apes (Chimpanzee Sequencing and Analysis Consortium, 2005; Kronenberg et al., 2018). In striking contrast, a compendium of nearly hundred thousand candidate human-specific regulatory sequences (HSRS) has been assembled in recent years (Glinsky et al., 2015-2019; Kanton et al., 2019), thus validating the idea that unique to human phenotypes may result from human-specific changes to genomic regulatory sequences defined as "regulatory mutations" (King and Wilson, 1975). The best evidence of the exquisite degree of accuracy of the contemporary molecular definition of human-specific regulatory sequences is identification of 35,074 single nucleotide changes (SNCs) that are fixed in humans, distinct from other primates, and located within differentially-accessible (DA) chromatin regions during the human brain development in cerebral organoids (Kanton et al., 2019). However, only a small fraction of identified DA chromatin peaks (600 of 17,935 DA peaks; 3.3%) manifest associations with differential expression in human versus chimpanzee cerebral organoids model of brain development, consistent with the hypothesis that regulatory effects on gene expression of these chromatin regions are not restricted to the early stages of brain development. Annotation of SNCs derived and fixed in modern humans that overlap DA chromatin regions during brain development revealed that essentially all candidate regulatory human-specific SNCs are shared with the archaic humans (35,010 SNCs; 99.8%) and only 64 SNCs are unique to modern humans (Kanton et al., 2019). This remarkable conservation on the human lineage of human-specific SNCs associated with human brain development sows the seed of interest for in-depth exploration of coding genes expression of which may be affected by genetic regulatory loci harboring human-specific SNCs. The GREAT algorithm (McLean et al., 2010, 2011) was utilized to identify 8,405 genes expression of which might be affected by 35,074 human-specific SNCs located in DA chromatin regions during brain development. Comprehensive gene set enrichment analyses of these genes revealed the staggering breadth of associations with physiological processes and pathological conditions of *H. sapiens*, including more than 1,000 anatomically-distinct regions of

the adult human brain, many human tissues and cell types, more than 200 common human disorders and 1,116 rare diseases.

Results and discussion

Identification and characterization of putative genetic regulatory targets associated with human-specific single nucleotide changes (SNCs) in in differentially accessible (DA) chromatin regions during brain development

To identify and characterize human genes associated with 35,074 human-specific single nucleotide changes (SNCs) in differentially accessible (DA) chromatin regions during human and chimpanzee neurogenesis in cerebral organoids (Kanton et al., 2019), the GREAT algorithm (McLean et al., 2011) have been employed. These analyses identified 8,405 genes with putative regulatory connections to human-specific SNCs (Figure 1) and revealed a remarkable breadth of highly significant associations with a multitude of biological processes, molecular functions, genetic and metabolic pathways, cellular compartments, and gene expression perturbations (Supplemental Table Set S1).

It has been noted that particularly striking numbers of significant associations were uncovered by the GREAT algorithm during the analyses of two databases:

1) The Human Phenotype Ontology containing over 13,000 terms describing clinical phenotypic abnormalities that have been observed in human diseases, including hereditary disorders (326 significant records with binominal FDR Q-Value < 0.05);

2) The MGI Expression Detected ontology referencing genes expressed in specific anatomical structures at specific developmental stages (Theiler stages) in the mouse (370 significant records with binominal FDR Q-Value < 0.05).

These observations support the hypothesis that biological functions of genes under the putative regulatory control of human-specific SNCs in DA chromatin regions during brain development are not limited to the contribution to the early stages of neuro- and corticogenesis. Collectively, findings reported in the Supplemental Table Set S1 argue that genes expression of which is affected by human-specific SNCs may

represent a genomic dominion of putative regulatory dependency from HSRS that is likely to play an important role in a broad spectrum of physiological processes and pathological conditions of Modern Humans.

Identification of genes expression of which distinguishes thousands of anatomically distinct areas of the adult human brain, various regions of the central nervous system, and many different cell types and tissues in the human body

To validate and extend these observations, next the comprehensive gene set enrichment analyses were performed employing the web-based Enrichr API protocols (Chen et al., 2013; Kuleshov et al., 2016), which interrogated nearly 200,000 gene sets from more than 100 gene set libraries. The results of these analyses are summarized in the Table 1 and reported in details in the Supplemental Table Set S2. Genes expression of which were placed during evolution under the regulatory control of ~ 35,000 human-specific SNCs demonstrate a staggering breadth of significant associations with a broad spectrum of anatomically distinct regions, various cell and tissue types, a multitude of physiological processes, and a numerous pathological conditions of *H. sapiens*.

Of particular interest is the apparent significant enrichment of human-specific SNCs-associated genes among both up-regulated and down-regulated genes, expression of which discriminates thousands of anatomically distinct areas of the adult human brain defined in the Allen Brain Atlas (Figure 2; Supplemental Table Set S2). Notably, genes expressed in various thalamus regions appear frequently among the top-scored anatomical areas of the human brain (Figure 2; Supplemental Table Set S2). These observations support the hypothesis that genetic loci harboring human-specific SNCs may exert regulatory effects on structural and functional features of the adult human brain, thus, likely affecting the development and functions of the central nervous system in Modern Humans. Consistent with this idea, the examination of the enrichment patterns of human-specific SNCs-associated genes in the ARCHS4 Human Tissues' gene expression database revealed that top 10 most significantly enriched records overlapping a majority of region-specific marker genes constitute various anatomically-distinct regions of the central nervous system (Figure 2; Supplemental Table Set S2). However, results of gene set enrichment analyses convincingly demonstrate that inferred regulatory effects of genetic loci harboring human-specific SNCs are not restricted only to the various regions of the central nervous

system, they appear to affect gene expression profiles of many different cell types and tissues in the human body (Table 1; Supplemental Table Set S2).

Identification and characterization of genes expression of which is altered during aging of humans, rats, and mice

Genes altered expression of which is implicated in the aging of various tissues and organs of humans, rats, and mice are significantly enriched among 8,405 genes associated with human-specific regulatory SNCs (Figure 3; Supplemental Table Set S2). Aging of the hippocampus was implicated most frequently among genes manifesting increased expression with age, while among genes exhibiting aging-associated decreased expression the hippocampus and frontal cortex were identified repeatedly (Figure 3). Overall, twice as many significant association records were observed among aging-associated down-regulated genes compared to up-regulated genes (Table 1). Collectively, these observations indicate that genes changes in expression of which were associated with aging in mammals, in particular, hippocampal and frontal cortex aging, represent important elements of a genomic dominion that was placed under regulatory control of genetic loci harboring human-specific SNCs.

Identification of genes implicated in development and manifestations of hundreds physiological and pathological phenotypes and autosomal inheritance in Modern Humans

Interrogations of the Human Phenotype Ontology database (298 significantly enriched records identified), the Genome-Wide Association Study (GWAS) Catalogue (241 significantly enriched records identified), and the database of Human Genotypes and Phenotypes (136 significantly enriched records identified) revealed several hundred physiological and pathological phenotypes and thousands of genes manifesting significant enrichment patterns defined at the adjusted p value < 0.05 (Figure 4; Table 1; Supplemental Table Set S2). Interestingly, 645 and 849 genes implicated in the autosomal dominant (HP:0000006) and recessive (HP:0000007) inheritance were identified amongst genes associated with human-specific regulatory SNCs (Figure 4; Supplemental Table Set S2). Notable pathological conditions among top-scored records identified in the database of Human Genotypes and Phenotypes are stroke, myocardial infarction, coronary artery disease, and heart failure (Figure 4).

A total of 241 significantly enriched records (Table 1) were documented by gene set enrichment analyses of the GWAS catalogue (2019), among which a highly diverse spectrum of pathological conditions linked to genes associated with human-specific regulatory SNCs was identified, including obesity, type 2 diabetes, amyotrophic lateral sclerosis, autism spectrum disorders, attention deficit hyperactivity disorder, bipolar disorder, major depressive disorder, schizophrenia, Alzheimer's disease, malignant melanoma, diverticular disease, asthma, coronary artery disease, glaucoma, as well as breast, prostate and colorectal cancers (Figure 4; Supplemental Table Set S2). These observations indicate that thousands of genes putatively associated with genetic regulatory loci harboring human-specific SNCs affect risk of developing numerous pathological conditions in Modern Humans.

Identification of genes expression of which is altered in several hundred common human disorders

Gene set enrichment analyses-guided interrogation of the Gene Expression Omnibus (GEO) database revealed the remarkably diverse spectrum of human diseases with the etiologic origins in multiple organs and tissues and highly heterogeneous pathophysiological trajectories of their pathogenesis (Figure 5; Supplemental Table Set S2). Overlapping gene sets between disease-associated genes and human-specific SNCs-linked genes comprise of hundreds of genes that were either up-regulated (204 significant disease records) or down-regulated (240 significant disease records) in specific pathological conditions, including schizophrenia, bipolar disorder, various types of malignant tumors, Crohn's disease, ulcerative colitis, Down syndrome, Alzheimer's disease, spinal muscular atrophy, multiple sclerosis, autism spectrum disorders, type 2 diabetes mellitus, morbid obesity, cardiomyopathy (Figure 5; Supplemental Table Set S2). These observations demonstrate that thousands of genes expression of which is altered in a myriad of human diseases appear associated with genetic regulatory loci harboring human-specific SNCs.

Identification of genes implicated in more than 1,000 records classified as human rare diseases

Present analyses demonstrate that thousands of genes associated with human-specific regulatory SNCs have been previously identified as genetic elements affecting the likelihood of development a multitude of common human disorders. Similarly, thousands of genes expression of which is altered during development and manifestation of multiple common human disorders appear linked to genetic regulatory loci harboring human-

specific SNCs. Remarkably, interrogations of the Enrichr's libraries of genes associated with Modern Humans' rare diseases identified 473, 603, 641, and 1,116 significantly enriched records of various rare disorders employing the Rare Diseases GeneRIF gene lists library, the Rare Diseases GeneRIF ARCHS4 predictions library, the Rare Diseases AutoRIF ARCHS4 predictions library, and the Rare Diseases AutoRIF Gene lists library, respectively (Figure 6; Supplemental Table Set S2). Taken together, these observations demonstrate that thousands of genes associated with hundreds of human rare disorders appear linked with human-specific regulatory SNCs.

Gene ontology analyses of putative regulatory targets of genetic loci harboring human-specific SNCs

Gene Ontology (GO) analyses identified a constellation of biological processes (GO Biological Process: 308 significant records) supplemented with a multitude of molecular functions (GO Molecular Function: 81 significant records) that appear under the regulatory control of human-specific SNCs (Figure 7; Supplemental Table Set 2). Consistently, both databases identified frequently the components of transcriptional regulation and protein kinase activities among most significant records. Other significantly enriched records of interest are regulation of apoptosis, cell proliferation, migration, and various binding properties (cadherin binding; sequence-specific DNA binding; protein-kinase binding; amyloid-beta binding; actin binding; tubulin binding; microtubule binding; PDZ domain binding) which are often supplemented by references to the corresponding activity among the enriched records, for example, enriched records of both binding and activity of protein kinases.

Interrogation of GO Cellular Component database identified 29 significantly enriched records, among which nuclear chromatin as well as various cytoskeleton and membrane components appear noteworthy (Figure 7). Both GO Biological Process and GO Cellular Component database identified significantly enriched records associated with the central nervous system development and functions such as axonogenesis and axon guidance; generation of neurons, neuron differentiation, and neuron projection morphogenesis; cellular components of dendrites and dendrite's membrane; ionotropic glutamate receptor complex. In several instances biologically highly consistent enrichment records have been identified in different GO databases: cadherin binding (GO Molecular Function) and catenin complex (GO Cellular Component); actin binding (GO

Molecular Function) and actin cytoskeleton, cortical actin cytoskeleton, actin-based cell projections (GO Cellular Component); microtubule motor activity, tubulin binding, microtubule binding (GO Molecular Function) and microtubule organizing center, microtubule cytoskeleton (GO Cellular Component).

Analyses of human and mouse databases of the Kyoto Encyclopedia of Genes and Genomes (KEGG; Figure 8) identified more than 100 significantly enriched records in each database (KEGG 2019 Human (2019): 129 significant records; KEGG 2019 Mouse: 106 significant records). Genes associated with human-specific regulatory SNCs were implicated in a remarkably broad spectrum of signaling pathways ranging from pathways regulating the pluripotency of stem cells to cell type-specific morphogenesis and differentiation pathways, for example, melanogenesis and adrenergic signaling in cardiomyocytes (Figure 8). Genes under putative regulatory control of human-specific SNCs include hundreds of genes contributing to specific functions of specialized differentiated cells (gastric acid secretion; insulin secretion; aldosterone synthesis and secretion), multiple receptor/ligand-specific signaling pathways, as well as genetic constituents of pathways commonly deregulated in cancer and linked to the organ-specific malignancies, for example, breast, colorectal, and small cell lung cancers (Figure 8). Other notable entries among most significantly enriched records include axon guidance; dopaminergic, glutamatergic, and cholinergic synapses; neuroactive receptor-ligand interactions; and AGE-RAGE signaling pathway in diabetic complications (Figure 8; Supplemental Table Set 2).

Structurally, functionally, and evolutionary distinct classes of HSRS share the relatively restricted elite set of common genetic targets

It has been suggested that unified activities of thousands candidate HSRS comprising a coherent compendium of genomic regulatory elements markedly distinct in their structure, function, and evolutionary origin may have contributed to development and manifestation of human-specific phenotypic traits (Glinsky, 2019). It was interest to determine whether genes previously linked to other classes of HSRS, which were identified without considerations of human-specific SNCs, overlap with genes associated in this contribution with genomic regulatory loci harboring human-specific SNCs. It was observed that the common gene set comprises of 7,406 coding genes (88% of all human-specific SNCs-associated genes), indicating that structurally-diverse HSRS,

the evolutionary origin of which has been driven by mechanistically-distinct processes, appear to favor the regulatory alignment with the relatively restricted elite set of genetic targets (Figure 9).

Previous studies have identified stem cell-associated retroviral sequences (SCARS) encoded by human endogenous retroviruses LTR7/HERVH and LTR5_Hs/HERVK as one of the significant sources of the evolutionary origin of HSRS (Glinsky, 2015-2019), including human-specific transcription factor binding sites (TFBS) for NANOG, OCT4, and CTCF (Glinsky, 2015). Next, the common sets of genetic regulatory targets were identified for genes expression of which is regulated by SCARS and genes associated in this study with human-specific regulatory SNCs (Figure 9). It has been determined that each of the structurally-distinct families of SCARS appears to share a common set of genetic regulatory targets with human-specific SNCs (Figure 9). Overall, expression of nearly half (4,029 genes; 48%) of all genes identified as putative regulatory targets of human-specific SNCs is regulated by SCARS (Figure 9). Consistent with the idea that structurally-diverse HSRS may favor the relatively restricted elite set of genetic targets, the common gene set of regulatory targets for HSRS, SCARS, and SNCs comprises of 7,833 coding genes or 93% of all genes associated in this contribution with human-specific regulatory SNCs (Figure 9).

To gain insights into mechanisms of SCARS-mediated effects on expression of 4,029 genes linked to human-specific regulatory SNCs, the numbers of genes expression of which was either activated (down-regulated following SCARS silencing) or inhibited (up-regulated following SCARS silencing) by SCARS have been determined. It was observed that SCARS exert the predominantly inhibitory effect on expression of genes associated with human-specific regulatory SNCs, which is exemplified by activated expression of as many as 87% of genes affected by SCARS silencing (Figure 9).

Identification of 2,273 genes associated with human-specific SNCs and implicated in premature death and embryonic, perinatal, neonatal, and postnatal lethality phenotypes

Interrogation of MGI Mammalian Phenotype databases revealed several hundred mammalian phenotypes affected by thousands of genes associated with genomic regulatory regions harboring human-specific SNCs: the MGI Mammalian Phenotype (2017) database identified 749 significant enrichment records, while the MGI Mammalian Phenotype Level 4 (2019) database identified 407 significant enrichment records (Figure 10;

Supplemental Table Set S2). Strikingly, present analyses identified a total of 2,273 genes that are associated with premature death, embryonic survival, and perinatal, neonatal, and postnatal lethality phenotypes of both complete and incomplete penetrance (Figure 11) and appear under regulatory control of genetic loci harboring genes essential for human-specific SNCs. A significant fraction of these 2,273 offspring survival were implicated in the autosomal dominant (389 genes) and recessive (426 genes) inheritance in Modern Humans (Figure 11). Based on these observations, it has been concluded that thousands of genes within the genomic dominion of putative regulatory dependency from human-specific SNCs represent the essential genetic elements of the survival of species phenotypes.

Methods

Data source and analytical protocols

Candidate human-specific regulatory sequences and African Apes-specific retroviral insertions

A total of 94,806 candidate HSRS, including 35,074 human-specific SNCs, detailed descriptions of which and corresponding references of primary original contributions are reported elsewhere (Glinsky et al., 2015-2019; Kanton et al., 2019). Solely publicly available datasets and resources were used in this contribution. The significance of the differences in the expected and observed numbers of events was calculated using two-tailed Fisher's exact test. Additional placement enrichment tests were performed for individual classes of HSRS taking into account the size in bp of corresponding genomic regions.

Data analysis

Categories of DNA sequence conservation

Identification of highly-conserved in primates (pan-primate), primate-specific, and human-specific sequences was performed as previously described (Glinsky, 2015-2019). In brief, all categories were defined by direct and reciprocal mapping using LiftOver. Specifically, the following categories of candidate regulatory sequences were distinguished:

- Highly conserved in primates' sequences: DNA sequences that have at least 95% of bases remapped during conversion from/to human (Homo sapiens, hg38), chimp (Pan troglodytes, v5), and bonobo (Pan paniscus, v2; in specifically designated instances, Pan paniscus, v1 was utilized for comparisons).

Similarly, highly-conserved sequences were defined for hg38 and latest releases of genomes of Gorilla, Orangutan, Gibbon, and Rhesus.

- Primate-specific: DNA sequences that failed to map to the mouse genome (mm10).
- Human-specific: DNA sequences that failed to map at least 10% of bases from human to both chimpanzee and bonobo. All candidate HSRS identified based on the sequence alignments failures to genomes of both chimpanzee and bonobo were subjected to more stringent additional analyses requiring the mapping failures to genomes of Gorilla, Orangutan, Gibbon, and Rhesus. These loci were considered created *de novo* human-specific regulatory sequences (HSRS).

To infer the putative evolutionary origins, each evolutionary classification was defined independently by running the corresponding analyses on all candidate HSRS representing the specific category. For example, human-rodent conversion identify sequences that are absent in the mouse genome based on the sequence identity threshold of 10%). Additional comparisons were performed using the same methodology and exactly as stated in the manuscript text and described in details below.

Genome-wide proximity placement analysis

Genome-wide Proximity Placement Analysis (GPPA) of distinct genomic features co-localizing with HSRS was carried out as described previously (Glinsky, 2015-2019). Briefly, a typical example of the analytical protocol is described below. The significance of overlaps between hESC active enhances and human-specific transcription factor binding sites (hsTFBS) was examined by first identifying all hsTFBS that overlap with any of the genomic regions tested in the ChIP-STARR-seq dataset (Barakat etl, 2018; Glinsky et al., 2018-2019). Then, the relative frequency of active enhancers overlapping with hsTFBS was calculated. To assess the significance of the observed overlap of genomic coordinates, the values recorded for hsTFBS were compared with the expected frequency of active and non-active enhancers that overlap with all TFBS for NANOG (15%) and OCT4 (25%) as previously determined (Barakat et al 2018). The analyses demonstrated that more than 95% of hsTFBS co-localized with sequences in the tested regions of the hESC genome.

The Enrichr API (January 2018 through October 2019 releases) (Chen et al., 2013; Kuleshov et al., 2016) was used to test genes linked to HSRS of interest for significant enrichment in numerous functional

categories. In all tables and plots (unless stated otherwise), the "combined score" calculated by Enrichr is reported, which is a product of the significance estimate and the magnitude of enrichment (combined score c = $log(p) * z$, where p is the Fisher's exact test p-value and z is the z-score deviation from the expected rank). When technically feasible, larger sets of genes comprising several thousand entries were analyzed. Regulatory connectivity maps between HSRS and coding genes and additional functional enrichment analyses were performed with the GREAT algorithm (McLean et al., 2010; 2011) at default settings.

Statistical Analyses of the Publicly Available Datasets

All statistical analyses of the publicly available genomic datasets, including error rate estimates, background and technical noise measurements and filtering, feature peak calling, feature selection, assignments of genomic coordinates to the corresponding builds of the reference human genome, and data visualization, were performed exactly as reported in the original publications and associated references linked to the corresponding data visualization tracks (http://genome.ucsc.edu/). Any modifications or new elements of statistical analyses are described in the corresponding sections of the Results. Statistical significance of the Pearson correlation coefficients was determined using GraphPad Prism version 6.00 software. Both nominal and Bonferroni adjusted p values were estimated. The significance of the differences in the numbers of events between the groups was calculated using two-sided Fisher's exact and Chi-square test, and the significance of the overlap between the events was determined using the hypergeometric distribution test (Tavazoie et al., 1999).

Supplemental Information

Supplemental information includes Supplemental Tables S1 and S2, Supplemental Text, and Supplemental Figures.

Author Contributions

This is a single author contribution. All elements of this work, including the conception of ideas, formulation, and development of concepts, execution of experiments, analysis of data, and writing of the paper, were performed by the author.

Acknowledgements

This work was made possible by the open public access policies of major grant funding agencies and international genomic databases and the willingness of many investigators worldwide to share their primary research data. I would like to thank my anonymous colleagues for their valuable critical contributions during the peer review process of this work.

References

Barakat TS, Halbritter F, Zhang M, Rendeiro AF, Perenthaler E, Bock C, Chambers I. 2018. Functional dissection of the enhancer repertoire in human embryonic stem cells. Cell Stem Cell. 2018; 23: 276-288.e8. doi: 10.1016/j.stem.2018.06.014. Epub 2018 Jul 19.

Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128. doi: 10.1186/1471-2105-14-128.

Chimpanzee Sequencing and Analysis Consortium, Initial sequence of the chimpanzee genome and comparison with the human genome. 2005. Nature 437, 69–87.

Glinsky GV. 2015. Transposable elements and DNA methylation create in embryonic stem cells human-specific regulatory sequences associated with distal enhancers and non-coding RNAs. Genome Biol Evol 7: 1432-1454.

Glinsky GV. 2016. Mechanistically distinct pathways of divergent regulatory DNA creation contribute to evolution of human-specific genomic regulatory networks driving phenotypic divergence of Homo sapiens. Genome Biol Evol 8:2774-88.

Glinsky GV. 2016. Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors. Cancer Lett 376:347-359.

Glinsky GV. 2016. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors. Cancer Lett 381:176-93.

Glinsky GV. 2017. Human-specific features of pluripotency regulatory networks link NANOG with fetal and adult brain development. BioRxiv. https://www.biorxiv.org/content/early/2017/06/19/022913; doi: https://doi.org/10.1101/022913.

Glinsky GV. 2018. Contribution of transposable elements and distal enhancers to evolution of human-specific features of interphase chromatin architecture in embryonic stem cells. Chromosome Res. 2018. 26: 61-84.

Glinsky G, Durruthy-Durruthy J, Wossidlo M, Grow EJ, Weirather JL, Au KF, Wysocka J, Sebastiano V. 2018. Single cell expression analysis of primate-specific retroviruses-derived HPAT lincRNAs in viable human blastocysts identifies embryonic cells co-expressing genetic markers of multiple lineages. Heliyon 4: e00667. doi: 10.1016/j.heliyon.2018.e00667. eCollection 2018 Jun. PMID: 30003161.

Glinsky GV, Barakat TS. 2019. The evolution of Great Apes has shaped the functional enhancers' landscape in human embryonic stem cells. 37:101456. PMID: 31100635. DOI: 10.1016/j.scr.2019.101456

Glinsky GV. 2019. A catalogue of 59,732 human-specific regulatory sequences reveals unique to human regulatory patterns associated with virus-interacting proteins, pluripotency and brain development. DNA and Cell Biology, in press.

Guffanti G, Bartlett A, Klengel T, Klengel C, Hunter R, Glinsky G, Macciardi F. 2018. Novel bioinformatics approach identifies transcriptional profiles of lineage-specific transposable elements at distinct loci in the human dorsolateral prefrontal cortex. Mol Biol Evol. 35: 2435-2453. PMID: 30053206. PMCID: PMC6188555. DOI: 10.1093/molbev/msy143.

Kanton S, Boyle MJ, He Z, Santel M, Weigert A, Sanchís-Calleja F, Guijarro P, Sidow L, Fleck JS, Han D, Qian Z, Heide M, Huttner WB, Khaitovich P, Pääbo S, Treutlein B, Camp JG. 2019. Organoid single-cell genomic atlas uncovers human-specific features of brain development. Nature. 2019; 574: 418-422. PMID: 31619793; DOI: 10.1038/s41586-019-1654-9.

King MC, Wilson AC. 1975. Evolution at two levels in humans and chimpanzees. Science 188: 107-116. https://doi.org/10.1126/science.1090005

Kronenberg ZN, et al. 2018. High-resolution comparative analysis of great ape genomes. Science 360: eaar6343.

Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research. 2016; gkw377.

McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schaar, B.T., Lowe, C.B., Wenger, A.M., Bejerano, G. 2011. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 28: 495-501.

McLean CY, Reno PL, Pollen AA, Bassan AI, Capellini TD, Guenther C, Indjeian VB, Lim X, Menke DB, Schaar BT, Wenger AM, Bejerano G, Kingsley DM. 2011. Human-specific loss of regulatory DNA and the evolution of human-specific traits. Nature **471**: 216-9.

Table 1. Associations with human physiological processes and pathological conditions of 8,405 genes linked with 35,074 human-specific single nucleotide changes (SNC) within differentially-accessible (DA) chromatin regions identified during human and chimpanzee brain development in cerebral organoids.

Database	Number of significant records*
ARCHS4 Human Tissues	39
Human Brain Regions: Allen Brain Atlas (Up-regulated genes)	1,200
Human Brain Regions: Allen Brain Atlas (Down-regulated genes)	1,062
Aging Perturbations from GEO (Up-regulated genes)	34
Aging Perturbations from GEO (Down-regulated genes)	67
GO Biological Process	308
GO Molecular Function	81
GO Cellular Component	29
KEGG 2019 Human	129
KEGG 2019 Mouse	106
MGI Mammalian Phenotype 2017	749
MGI Mammalian Phenotype Level 4 2019	407
Human Phenotype Ontology	298
GWAS Catalog 2019	241
Database of Human Genotypes and Phenotypes (dbGaP)	136
Disease Perturbations from GEO (Up-regulated genes)	204
Disease Perturbations from GEO (Down-regulated genes)	240
Rare Diseases GeneRIF Gene Lists	473
Rare Diseases GeneRIF ARCHS4 Predictions	603
Rare Diseases AutoRIF ARCHS4 Predictions	641
Rare Diseases AutoRIF Gene Lists	1,116

Legend: *, defined at adjusted p-value < 0.05; GEO, gene expression omnibus; GO, gene ontologies; GWAS, genome-wide association studies; ARCHS4, all RNA-seq and ChIP-seq sample and signature search; KEGG, Kyoto Encyclopedia of Genes and Genomes; MGI, mouse genome informatics;



Figure 1. GREAT analysis identifies 8,405 human genes associated with 35,074 human-specific single nucleotide changes (SNCs) in differentially accessible (DA) chromatin regions during human and chimpanzee brain development in cerebral organoids. A total of 1,064 of all 35,074 SNCs (3%) are not associated with any genes in the human genome, while a total of 34,010 human-specific SNCs in DA regions appear associated with 8,405 human genes.

ARCHS4 Human Tissues: 8,045 genes



ARCHS4 Human Tissues: 8,045 genes
Top 10 of 39 significant records

Term	Overlap	P-value	Adjusted P-value
PREFRONTAL CORTEX	1348/2316	2.06686E-62	2.23E-60
SPINAL CORD	1299/2316	1.17222E-47	4.22E-46
SPINAL CORD (BULK)	1299/2316	1.17222E-47	4.22E-46
CINGULATE GYRUS	1279/2316	3.13703E-42	8.47E-41
NEURONAL EPITHELIUM	1258/2316	6.71385E-37	1.45E-35
CEREBRAL CORTEX	1253/2316	1.09815E-35	1.98E-34
BRAIN (BULK)	1241/2316	7.35673E-33	1.14E-31
CEREBELLUM	1218/2316	8.73598E-28	1.18E-26
MOTOR NEURON	1184/2316	4.19448E-21	5.03E-20
SUPERIOR FRONTAL GYRUS	1181/2316	1.4634E-20	1.58E-19

Allen Brain Atlas Up: 8,045 genes



Allen Brain Atlas Up: 8,045 genes
Networks



Allen Brain Atlas Up: 8,045 genes



Allen Brain Atlas Up: 8,045 genes
Networks



Allen Brain Atlas Up: 8,045 genes
Top 30 of 1,200 significant records

Term	Overlap	P-value	Adjusted P-value
Thalamus, sensory-motor cortex related	207/301	3.57E-21	7.82E-18
Thalamus	222/334	9.71E-20	2.42E-17
mantle zone of DTTh	204/301	9.94E-20	2.42E-17
lateral part of alar p2	204/301	9.94E-20	2.42E-17
Ventral posterior complex of the thalamus	204/301	9.94E-20	2.42E-17
Central lateral nucleus of the thalamus	204/301	9.94E-20	2.42E-17
alar plate of p2 (alar thalamus)	204/301	9.94E-20	2.42E-17
submedius thalamic nucleus	204/301	9.94E-20	2.42E-17
dorsal tier of thalamus	204/301	9.94E-20	2.42E-17
Rhomboid nucleus	227/345	2.51E-19	5.34E-17
ventral nuclei	203/301	2.92E-19	5.34E-17
Ventral group of the dorsal thalamus	203/301	2.92E-19	5.34E-17
Field CA3, stratum pyramidale	202/301	8.47E-19	1.24E-16
Ventral posteromedial nucleus of the thalamus	202/301	8.47E-19	1.24E-16
ventral posteromedial nucleus	202/301	8.47E-19	1.24E-16
intermediate stratum of DTTh	201/301	2.42E-18	2.94E-16
prosomere 2	201/301	2.42E-18	2.94E-16
central lateral nucleus	201/301	2.42E-18	2.94E-16
dorsal lateral geniculate nucleus	200/301	6.79E-18	7.84E-16
hilus of the DG	199/301	1.88E-17	2.06E-15
lateral (parvicellular) part of MD	198/301	5.13E-17	4.33E-15
Dorsal part of the lateral geniculate complex	198/301	5.13E-17	4.33E-15
Ventral posterolateral nucleus of the thalamus	198/301	5.13E-17	4.33E-15
posterior (ventral) nucleus	198/301	5.13E-17	4.33E-15
Hippocampal formation	198/301	5.13E-17	4.33E-15
intralaminar nuclei	198/301	5.13E-17	4.33E-15
intermediate stratum of DG	353/597	9.09E-17	7.38E-15
Field CA3, stratum radiatum	219/342	1.17E-16	9.12E-15
mantle zone of CA	197/301	1.38E-16	9.76E-15
Thalamus, polymodal association cortex related	197/301	1.38E-16	9.76E-15







Allen Brain Atlas Down: 8,045 genes
Top 31 of 1,062 significant records

Term	Overlap	P-value	Adjusted P-value
Primary motor area	195/300	5.73E-16	1.26E-12
layer 3 of FCx	194/300	1.49E-15	1.63E-12
layer 4 of FCx	193/300	3.81E-15	2.79E-12
Somatomotor areas	189/300	1.42E-13	7.77E-11
layer 4 of PCx	188/300	3.38E-13	1.48E-10
Field CA2, stratum lacunosum-moleculare	248/426	8.01E-12	2.93E-09
Secondary motor area	183/300	2.1E-11	6.57E-09
Field CA2, stratum radiatum	262/458	2.75E-11	7.54E-09
Primary motor area, Layer 5	182/300	4.59E-11	9.16E-09
layer 5 of PCx	182/300	4.59E-11	9.16E-09
superficial stratum of m1B	182/300	4.59E-11	9.16E-09
r3 alar plate	181/300	9.92E-11	1.67E-08
parietal cortex	181/300	9.92E-11	1.67E-08
mantle zone of PCx	180/300	2.11E-10	2.44E-08
layer 3 of PCx	180/300	2.11E-10	2.44E-08
Pontine gray	180/300	2.11E-10	2.44E-08
r6 alar plate	183/300	2.11E-10	2.44E-08
superficial stratum of PCx (cortical plate/marginal zone)	180/300	2.11E-10	2.44E-08
superficial stratum of p2B	180/300	2.11E-10	2.44E-08
intralaminar nuclei	179/300	4.44E-10	4.64E-08
pontine hindbrain	182/300	4.44E-10	4.64E-08
Field CA3, stratum radiatum	211/364	4.83E-10	4.81E-08
Primary somatosensory area	178/300	9.2E-10	8.07E-08
frontal cortex	179/300	9.2E-10	8.07E-08
Somatosensory areas	178/300	9.2E-10	8.07E-08
mantle zone of FCx	178/300	1.88E-09	1.37E-07
layer 3 of OCx	177/300	1.88E-09	1.37E-07
r3 basal plate	177/300	1.88E-09	1.37E-07
superficial stratum of FCx (cortical plate/marginal zone)	178/300	1.88E-09	1.37E-07
oval paracentral nucleus	177/300	1.88E-09	1.37E-07
Primary motor area, Layer 2/3	176/300	3.79E-09	2.6E-07

Figure 2. Identification of genes expression of which distinguishes thousands of anatomically distinct areas of the adult human brain, various regions of the central nervous system, and many different cell types and tissues in the human body.

Aging Perturbations from GEO up: 8,405 genes



Aging Perturbations from GEO up: 8,405 genes
Top 30 significant records

Term	Overlap	P-value	Adjusted P-value
Human_Malignant Peripheral Nerve Sheath Tumour_24 years vs 53 years_GSE17118_aging:364	197/337	6.9E-10	1.97E-07
Mouse_hypothalamus_42 days vs 182 days_GDS3895_aging:107	201/349	2.59E-09	3.7E-07
Human_Malignant Peripheral Nerve Sheath Tumour_27 years vs 61 years_GSE17118_aging:363	195/343	1.78E-08	1.5E-06
Mouse_neuroretinas_7 weeks vs 64 weeks_GSE38671_aging:211	168/289	2.1E-08	1.5E-06
Mouse_retina_4 months vs 10 months_GSE33674_aging:304	148/254	1.16E-07	6.63E-06
Rat_hippocampus_3 months vs 24 months_GSE14505_aging:346	230/429	6.82E-07	3.25E-05
Mouse_hippocampus_9 months vs 20 months_GSE48911_aging:391	243/459	1.23E-06	5.02E-05
Mouse_retina_6 months vs 10 months_GSE33674_aging:305	125/218	3.39E-06	0.000121
Human_brain (frontal cortex)_55 years vs 82 years_GSE53890_aging:229	171/313	4.05E-06	0.000129
Mouse_retina_3 months vs 16 months_GDS2654_aging:66	199/372	4.53E-06	0.00013
Human_mesenchymal stem cells (from bone marrow)_42 years vs 79 years_GSE35955_aging:293	133/238	1.03E-05	0.000255
Human_a_0 es vs 0 es_GDS5077_aging:106	172/319	1.07E-05	0.000255
Mouse_hippocampus_9 months vs 14 months_GSE48911_aging:390	254/494	1.28E-05	0.000283
Mouse_neuroretina_7 weeks vs 64 weeks_GSE38671_aging:210	171/319	1.76E-05	0.00036
Human_skeletal muscle_19 years vs 65 years_GDS4858_aging:10	140/259	5.77E-05	0.0011
Mouse_spinal cord_18 months vs 30 months_GDS1280_aging:1	172/331	0.000151	0.002697
Mouse_hippocampus_9 months vs 14 months_GSE48911_aging:384	246/494	0.000252	0.004247
Rat_femur_7 weeks vs 53 weeks_GDS509_aging:264	197/389	0.000331	0.005257
Rat_femur_28 weeks vs 54 weeks_GDS509_aging:271	193/383	0.000523	0.007575
Rat_femur_7 weeks vs 27 weeks_GDS509_aging:258	155/301	0.00053	0.007575
Mouse_hippocampus_2 months vs 15 months_GSE5078_aging:398	151/293	0.000593	0.008072
Rat_femur_10 weeks vs 30 weeks_GDS509_aging:260	123/236	0.001057	0.013739
Mouse_oculomotor nucleus_6 months vs 30 months_GDS1280_aging:6	140/273	0.001185	0.01473
Rat_femur_10 weeks vs 56 weeks_GDS509_aging:266	191/384	0.001248	0.014873
Mouse_hippocampus_9 months vs 20 months_GSE48911_aging:385	216/442	0.001959	0.022408
Human_biceps brachii muscles_24 years vs 70 years_GDS4858_aging:33	119/233	0.003152	0.034649
Rat_myocardium_18 weeks vs 22 weeks_GDS4025_aging:142	124/244	0.003271	0.034649
Rat_hippocampus CA3 region_6 months vs 25 months_GSE14724_aging:347	170/345	0.003642	0.036658
Mouse_brain_6 months vs 14 months_GSE15129_aging:313	189/387	0.003717	0.036658
Mouse_spinal cord_6 months vs 30 months_GDS1280_aging:3	197/405	0.003882	0.037008



Aging Perturbations from GEO down: 8,405 genes
Top 30 significant records

Term	Overlap	P-value	Adjusted P-value
Rat_hippocampus_7 months vs 21 months_GDS4019_aging:98	196/314	1.85E-13	5.28E-11
Human_a_0 es vs 0 es_GDS5077_aging:106	175/281	4.78E-12	6.83E-10
Human_meniscus_40 years vs 55 years_GSE45233_aging:209	189/320	4.76E-10	4.54E-08
Rat_frontal cortex_4 months vs 22 months_GDS3939_aging:99	192/327	6.86E-10	4.9E-08
Mouse_skeletal muscle precursor_12 months vs 24 months_GDS4892_aging:9	137/224	5.29E-09	3.02E-07
Mouse_brain_25 weeks vs 100 weeks_GSE41018_aging:400	178/311	3.83E-08	1.68E-06
Mouse_striatum_6 months vs 21 months_GDS4153_aging:78	164/283	4.12E-08	1.68E-06
Human_meniscus_28 years vs 47 years_GSE45233_aging:208	165/286	5.7E-08	2.04E-06
Mouse_brain_8 weeks vs 104 weeks_GSE20411_aging:311	224/408	8.36E-08	2.66E-06
Human_brain (frontal cortex)_28 years vs 100 years_GSE53890_aging:228	197/356	2.32E-07	6.64E-06
Human_CD4+Thyphocytes_61 years vs 81 years_GSE62373_aging:185	193/349	3.26E-07	8.48E-06
Human_CD4+lyphocytes_40 years vs 72 years_GSE62373_aging:163	203/373	7.65E-07	1.82E-05
Mouse_hippocampus_4 months vs 9 months_GSE48911_aging:387	230/430	8.6E-07	1.89E-05
Rat_hippocampus_7 months vs 21 months_GDS4019_aging:97	156/277	9.99E-07	2.04E-05
Mouse_cochlea_15 weeks vs 45 weeks_GSE35234_aging:164	142/250	1.58E-06	3.01E-05
Human_brain (frontal cortex)_55 years vs 82 years_GSE53890_aging:229	159/287	2.97E-06	5.31E-05
Human_retinalmacula_18 years vs 74 years_GSE32614_aging:150	182/336	4.14E-06	6.96E-05
Mouse_hippocampus_4 months vs 9 months_GSE48911_aging:381	226/429	4.52E-06	7.18E-05
Human_CD4+lyphocytes_40 years vs 61 years_GSE62373_aging:160	192/358	5.34E-06	7.77E-05
Human_CD4+Thyphocytes_29 years vs 81 years_GSE62373_aging:176	201/377	5.44E-06	7.77E-05
Human_CD4+lyphocytes_29 years vs 61 years_GSE62373_aging:154	184/342	6.43E-06	8.75E-05
Human_retinalperiphery_32 years vs 74 years_GSE32614_aging:151	160/293	8.42E-06	0.000109
Human_brain (frontal cortex)_28 years vs 82 years_GSE53890_aging:227	154/281	9.47E-06	0.000118
Rat_hippocampus CA3 region_6 months vs 25 months_GSE14724_aging:347	141/255	1.2E-05	0.000143
Mouse_cochlea_4 weeks vs 45 weeks_GSE35234_aging:161	145/268	4.04E-05	0.000463
Rat_hippocampus dentate gyrus_18 months vs 28 months_GSE21681_aging:357	124/225	4.78E-05	0.000522
Rat_hippocampus dentate gyrus_18 months vs 28 months_GSE21681_aging:358	147/273	4.93E-05	0.000522
Human_CD4+lyphocytes_40 years vs 81 years_GSE62373_aging:165	197/380	6.24E-05	0.000638
Human_CD4+lyphocytes_29 years vs 81 years_GSE62373_aging:156	215/419	6.73E-05	0.000664
Rat_hippocampus CA1_18 months vs 28 months_GSE21681_aging:353	144/270	0.000107	0.001004

Figure 3. Identification and characterization of genes expression of which is altered during aging of humans, rats, and mice.







Human Phenotype Ontology (8,405 genes): Top 35 of 298 significant records

Term	Overlap	P-value	Adjusted P-value
Autosomal dominant inheritance (HP:0000006)	645/1134	2.85E-25	5.07E-22
Downslanted palpebral fissures (HP:0000494)	127/188	1.17E-12	1.04E-09
Cryptorchidism (HP:0000028)	222/379	4.46E-11	2.64E-08
Autosomal recessive inheritance (HP:0000007)	849/1722	1.14E-10	5.07E-08
Radial deviation of finger (HP:0009466)	140/229	3.75E-09	1.11E-06
Hypertelorism (HP:0000316)	190/328	3.76E-09	1.11E-06
Brachydactyly syndrome (HP:0001156)	119/192	1.77E-08	4.5E-06
Frontal bossing (HP:0002007)	129/213	3.38E-08	7.51E-06
Clinodactyly of the 5th finger (HP:0004209)	118/192	4.03E-08	7.96E-06
Low-set, posteriorly rotated ears (HP:0000368)	158/276	2.14E-07	3.8E-05
Iris coloboma (HP:0000612)	72/110	5.77E-07	9.34E-05
Ventricular septal defect (HP:0001629)	106/176	7.99E-07	0.000113
Infantile onset (HP:0003593)	145/254	8.28E-07	0.000113
Specific learning disability (HP:0001328)	36/47	1.49E-06	0.000189
Pes planus (HP:0001763)	68/105	2.09E-06	0.000246
Dental malocclusion (HP:0000689)	55/81	2.21E-06	0.000246
Thin upper lip vermilion (HP:0000219)	38/51	2.5E-06	0.000261
Blepharophimosis (HP:0000581)	67/104	3.26E-06	0.000323
Pes cavus (HP:0001761)	80/129	3.55E-06	0.000323
High forehead (HP:0000348)	69/108	3.63E-06	0.000323
Aganglionic megacolon (HP:0002251)	63/97	4.26E-06	0.000361
Umbilical hernia (HP:0001537)	91/151	4.5E-06	0.000364
Atrial fibrillation (HP:0005110)	26/32	6.52E-06	0.000505
Telecanthus (HP:0000506)	55/83	6.96E-06	0.000516
Prominent nasal bridge (HP:0000426)	64/100	7.43E-06	0.000529
Absent hair (HP:0002298)	18/20	1.14E-05	0.000781
Delayed eruption of teeth (HP:0000684)	56/86	1.28E-05	0.000841
Variable expressivity (HP:0003828)	86/144	1.34E-05	0.00085
Ptosis (HP:0000508)	180/338	1.79E-05	0.001074
Abnormality of the upper arm (HP:0001454)	29/38	1.81E-05	0.001074
Progressive disorder (HP:0003676)	86/145	1.94E-05	0.001103
Depressed nasal bridge (HP:0005280)	127/228	1.99E-05	0.001103
Sporadic (HP:0003745)	42/61	2.05E-05	0.001103
Left ventricular hypertrophy (HP:0001712)	31/42	2.93E-05	0.0015
Postaxial hand polydactyly (HP:0001162)	53/82	2.95E-05	0.0015

Database of Human Genotypes and Phenotypes (dbGaP): 8,405 genes



Database of Human Genotypes and Phenotypes (dbGaP): 8,405 genes
Top 20 of 136 significant records

Term	Overlap	P-value	Adjusted P-value
Body Mass Index	313/437	1.02E-36	3.46E-34
Body Height	276/385	1.32E-32	2.23E-30
Blood Pressure	310/454	3.19E-30	3.59E-28
Echocardiography	204/273	2.47E-28	2.08E-26
Stroke	211/289	6.02E-27	4.07E-25
Triglycerides	180/244	4.77E-24	2.68E-22
Cholesterol, HDL	242/357	3.57E-23	1.72E-21
Body Weight	161/216	1.91E-22	8.05E-21
Cholesterol, LDL	210/304	7.78E-22	2.92E-20
Hip	151/202	2.39E-21	8.06E-20
Cholesterol	183/268	2.28E-18	7.02E-17
Myocardial Infarction	157/229	3.32E-16	9.36E-15
Coronary Artery Disease	140/205	2.16E-14	5.31E-13
Heart Failure	130/187	2.2E-14	5.31E-13
Hemoglobins	113/157	2.38E-14	5.37E-13
Erythrocyte Count	87/115	2.09E-13	4.41E-12
Heart Rate	110/155	2.47E-13	4.86E-12
Creatinine	73/92	2.59E-13	4.86E-12
Fibrinogen	69/86	4.29E-13	7.05E-12
Lipoproteins, VLDL	69/86	4.29E-13	7.05E-12

GWAS Catalog 2019: 8,405 genes



GWAS Catalog 2019 (8,405 genes): Top 40 of 241 significant records

Term	Overlap	P-value	Adjusted P-value
Menarche (age at onset)	154/212	1.12E-19	1.4E-16
Systolic blood pressure	389/657	1.62E-19	1.4E-16
Chin dimples	62/74	1.51E-13	8.68E-11
Pulse pressure	321/567	9.66E-13	4.16E-10
Photic sneeze reflex	55/65	1.6E-12	5.51E-10
Heel bone mineral density	478/898	3.09E-12	8.88E-10
Obesity-related traits	427/804	6.08E-11	1.72E-08
Diastolic blood pressure	348/646	4.87E-10	1.05E-07
Monobrow	58/76	1.19E-09	2.28E-07
Obesity	45/55	1.61E-09	2.78E-07
Height	288/527	2.32E-09	3.63E-07
Atrial fibrillation	146/240	2.83E-09	3.78E-07
BMI (adjusted for smoking behaviour)	58/77	2.85E-09	3.78E-07
Spherical equivalent or myopia (age of diagnosis)	120/191	4.87E-09	5.99E-07
Neuroticism	69/97	5.87E-09	6.74E-07
Hip circumference	52/69	1.83E-08	1.97E-06
Diverticular disease	100/156	2.04E-08	2.06E-06
Allergic rhinitis	77/114	3.13E-08	3E-06
Waist circumference	55/75	3.67E-08	3.33E-06
Myopia	52/70	4.2E-08	3.62E-06
Body mass index (joint analysis main effects and smoking interaction)	56/77	4.5E-08	3.69E-06
Hand grip strength	99/156	5.05E-08	3.96E-06
Total body bone mineral density	31/36	5.77E-08	4.32E-06
Waist-hip ratio	44/58	1.65E-07	1.14E-05
BMI in non-smokers	44/58	1.65E-07	1.14E-05
Type 2 diabetes	217/397	2.08E-07	1.38E-05
Restless legs syndrome	32/39	3.48E-07	2.22E-05
Blond vs. brown/black hair color	98/160	6.9E-07	4.25E-05
Waist circumference adjusted for BMI (adjusted for smoking behaviour)	56/81	7.21E-07	4.29E-05
Amyotrophic lateral sclerosis (sporadic)	109/182	8.3E-07	4.77E-05
PR interval	48/67	8.6E-07	4.78E-05
Motion sickness	27/32	1.01E-06	5.45E-05
Male-pattern baldness	143/251	1.15E-06	6E-05
Central corneal thickness	47/66	1.48E-06	7.14E-05
Paditaxel disposition in epithelial ovarian cancer	36/47	1.49E-06	7.14E-05
Autism spectrum disorder, ADHD, bipolar disorder, MDD, and schizophrenia (combined)	56/47	1.49E-06	7.14E-05
Rosacea symptom severity	87/141	1.84E-06	8.57E-05
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	54/79	1.98E-06	8.99E-05
Waist circumference adjusted for body mass index	80/128	2.29E-06	0.000101
Glaucoma (primary open-angle)	52/76	2.92E-06	0.000124

Figure 4. Identification of genes implicated in development and manifestations of hundreds physiological and pathological phenotypes and autosomal inheritance in Modern Humans.





Disease Perturbations from GEO down (8,405 genes): Top 30 of 240 significant records

Term	Overlap	P-value	Adjusted P-value
schizophrenia DOID-5419 human GSE25673 sample 892	242/337	6.49E-29	5.44E-26
Bipolar Disorder C0005586 human GSE5389 sample 302	256/395	2.78E-20	1.17E-17
esophagus squamous cell carcinoma DOID-3748 human GSE63941 sample 659	252/391	1.65E-19	4.6E-17
Crohn's disease DOID-8778 human GSE6731 sample 757	240/370	3.64E-19	7.63E-17
ulcerative colitis DOID-8577 human GSE6731 sample 759	246/384	1.4E-18	2.34E-16
esophagus squamous cell carcinoma DOID-3748 human GSE63941 sample 658	256/408	1.43E-17	2E-15
schizophrenia DOID-5419 human GSE25673 sample 891	182/274	2.18E-16	2.61E-14
idiopathic pulmonary fibrosis DOID-0050156 human GSE44723 sample 850	201/312	8.28E-16	8.68E-14
Androgen insensitivity syndrome C0039585 human GSE3871 sample 415	208/327	1.94E-15	1.81E-13
adrenoleukodystrophy DOID-10588 human GSE34309 sample 864	212/338	9.23E-15	7.75E-13
Huntington's disease DOID-12858 mouse GSE3621 sample 704	219/356	6.55E-14	5E-12
Dystonia C0393593 human GSE3064 sample 329	198/317	1.27E-13	8.89E-12
Nephroblastoma C0027708 human GSE2712 sample 418	248/419	6.95E-13	4.48E-11
Huntington's disease DOID-12858 mouse GSE3583 sample 929	183/293	1.08E-12	6.44E-11
Ulcerative Colitis C0009324 human GSE6731 sample 249	213/354	3.26E-12	1.82E-10
Breast Cancer C0006142 human GSE1378 sample 52	184/299	6.23E-12	3.27E-10
Down syndrome DOID-14250 human GSE42956 sample 1060	156/247	1.41E-11	6.95E-10
Primary open angle glaucoma C0339573 human GSE2705 sample 257	156/249	3.5E-11	1.63E-09
colitis DOID-0060180 human GSE6731 sample 761	211/359	8.78E-11	3.71E-09
Alzheimer's disease DOID-10652 human GSE4757 sample 592	216/369	8.85E-11	3.71E-09
Crohn's disease DOID-8778 human GSE6731 sample 758	162/263	1.01E-10	4.01E-09
prolactinoma DOID-5394 human GSE36314 sample 636	251/440	1.05E-10	4.01E-09
diabetes mellitus type 2 DOID-9352 human GSE12643 sample 766	204/346	1.22E-10	4.34E-09
type 2 diabetes mellitus DOID-9352 human GSE13760 sample 882	221/380	1.24E-10	4.34E-09
skin squamous cell carcinoma DOID-3151 human GSE45164 sample 657	177/295	2.98E-10	1E-08
prostate cancer DOID-10283 human GSE3868 sample 638	201/344	4.9E-10	1.58E-08
Dental cavity, complex C0399396 human GSE1629 sample 175	228/401	1.12E-09	3.49E-08
Alzheimer's disease DOID-10652 human GSE36980 sample 520	190/325	1.37E-09	4.1E-08
oligodendroglioma DOID-3181 human GSE15824 sample 858	183/313	2.71E-09	7.83E-08
breast cancer DOID-1612 human GSE3744 sample 978	247/443	2.84E-09	7.95E-08

Disease Perturbations from GEO up: 8,405 genes



Disease Perturbations from GEO up (8,405 genes): Top 30 of 204 significant records

Term	Overlap	P-value	Adjusted P-value
Spinal Muscular Atrophy C0026847 mouse GSE10599 sample 235	254/368	4.69E-26	3.93E-23
Down Syndrome C0013080 human GSE5390 sample 277	288/460	2.08E-19	8.72E-17
schizophrenia DOID-5419 human GSE25673 sample 891	215/326	1.48E-18	4.14E-16
Cardiomyopathy, Dilated C0007193 human GSE3585 sample 198	209/326	4.82E-16	1.01E-13
Primary open angle glaucoma C0339573 human GSE2705 sample 257	216/351	9.23E-14	1.55E-11
Diamond-Blackfan anaemia DOID-1339 human GSE14335 sample 472	231/382	1.88E-13	2.64E-11
idiopathic pulmonary fibrosis DOID-0050156 human GSE44723 sample 851	185/300	4.2E-12	5.03E-10
schizophrenia DOID-5419 human GSE25673 sample 892	165/263	8.13E-12	8.53E-10
adrenoleukodystrophy DOID-10588 human GSE34309 sample 864	164/262	1.23E-11	1.14E-09
idiopathic pulmonary fibrosis DOID-0050156 human GSE44723 sample 850	177/288	1.83E-11	1.5E-09
morbid obesity DOID-11981 human GSE48964 sample 583	180/294	1.96E-11	1.5E-09
Cardiomyopathy C0878544 human GSE1869 sample 79	197/330	5.63E-11	3.87E-09
Type 2 diabetes mellitus C0011860 human GSE12643 sample 274	205/346	5.99E-11	3.87E-09
GERD - Gastro-esophageal reflux disease C0017168 human GSE2144 sample 27	203/346	2.46E-10	1.48E-08
Uterine leiomyoma C0042133 human GSE2725 sample 399	158/258	3.19E-10	1.78E-08
multiple sclerosis DOID-2377 human GSE38010 sample 737	183/310	9.47E-10	4.96E-08
Chronic phase chronic myelogenous leukemia DOID-8552 human GSE5550 sample 456	192/330	1.92E-09	9.47E-08
autism spectrum disorder DOID-0060041 human GSE28521 sample 1041	185/317	2.71E-09	1.26E-07
Setleis syndrome C1744559 human GSE16524 sample 285	222/393	4E-09	1.77E-07
Neurofibromatosis DOID-8712 mouse GSE1482 sample 667	210/369	4.54E-09	1.9E-07
multiple sclerosis DOID-2377 human GSE38010 sample 738	180/309	5.36E-09	2.14E-07
Uterine leiomyoma C0042133 human GSE593 sample 16	160/270	7.23E-09	2.76E-07
autism spectrum disorder DOID-0060041 human GSE28521 sample 1040	194/341	1.8E-08	6.56E-07
Urothelial carcinoma in situ C0334267 human GSE3167 sample 229	213/380	1.94E-08	6.77E-07
Status Epilepticus C0038220 rat GSE4236 sample 391	191/336	2.51E-08	8.11E-07
autism spectrum disorder DOID-0060041 human GSE28521 sample 1039	191/336	2.51E-08	8.11E-07
adrenoleukodystrophy DOID-10588 human GSE34308 sample 709	205/365	2.88E-08	8.95E-07
Down Syndrome C0013080 human GSE10758 sample 310	210/376	3.57E-08	1.07E-06
chronic lymphocytic leukemia DOID-1040 human GSE6691 sample 786	180/315	3.77E-08	1.09E-06
Oligodendroglioma C0028945 human GSE2223 sample 116	167/289	4.08E-08	1.14E-06

Figure 5. Identification of genes expression of which is altered in several hundred common human disorders.



Top 20 of 473 significant records

Term	Overlap	P-value	Adjusted P-value
Hypothalamic_dysfunction	90/128	8.12E-11	6.55E-08
Exencephaly	158/256	1.38E-10	6.55E-08
Cerebellar_agenesis	198/335	1.7E-10	6.55E-08
Occult_spinal_dysraphism	157/255	2.05E-10	6.55E-08
Diastematomyelia	157/255	2.05E-10	6.55E-08
Craniorachischisis	157/255	2.05E-10	6.55E-08
Iniencephaly	157/255	2.05E-10	6.55E-08
Chromosomal_triplication	201/344	4.9E-10	1.37E-07
Weber_syndrome	94/139	8.85E-10	2.2E-07
Cluttering	106/162	1.41E-09	3.16E-07
Mental_retardation_epilepsy	190/326	1.92E-09	3.9E-07
Single_ventricular_heart	73/104	5.49E-09	1.02E-06
Sydenham's_chorea	209/369	8.42E-09	1.34E-06
Chorea_minor	209/369	8.42E-09	1.34E-06
Antisocial_personality_disorder	46/59	1.93E-08	2.87E-06
Sudden_infant_death_syndrome	103/162	2.37E-08	3.31E-06
Stress_cardiomyopathy	110/176	3.16E-08	4.16E-06
N_syndrome	222/401	3.89E-08	4.83E-06
Basilar_migraine	127/210	4.85E-08	5.7E-06
Corpus_callosum_agenesis	89/138	7.92E-08	8.85E-06





Top 20 of 603 significant records

Term	Overlap	P-value	Adjusted P-value
Lissencephaly_1	154/200	4.79E-24	1.08E-20
Adenoameloblastoma	151/200	4.35E-22	3.26E-19
Syndactyly_type_2	151/200	4.35E-22	3.26E-19
Axenfeld-Rieger_syndrome	150/200	1.85E-21	5.94E-19
Miller-Dieker_syndrome	150/200	1.85E-21	5.94E-19
Exostoses_multiple_type_2	150/200	1.85E-21	5.94E-19
Infantile_myofibromatosis	150/200	1.85E-21	5.94E-19
Neonatal_progeroid_syndrome	149/200	7.69E-21	2.16E-18
Polysyndactyly_type_4	148/200	3.11E-20	6.97E-18
Cystic_hygroma	148/200	3.11E-20	6.97E-18
Acromesomelic_dysplasia_Hunter_Thompson_type	147/200	1.22E-19	2.11E-17
Acromesomelic_dysplasia	147/200	1.22E-19	2.11E-17
Exostoses_multiple_type_1	147/200	1.22E-19	2.11E-17
Scholte_syndrome	146/200	4.69E-19	6.58E-17
Congenital_diaphragmatic_hernia	146/200	4.69E-19	6.58E-17
Hereditary_multiple_osteochondromas	146/200	4.69E-19	6.58E-17
Aortopulmonary_window	145/200	1.76E-18	1.88E-16
Corpus_callosum_agenesis	145/200	1.76E-18	1.88E-16
Apert_syndrome	145/200	1.76E-18	1.88E-16
Subependymoma	145/200	1.76E-18	1.88E-16





Top 20 of 641 significant records

Term	Overlap	P-value	Adjusted P-value
Metacarpals_4_and_5_fusion	163/200	1.33E-30	4.97E-27
Chromosome_3_duplication_syndrome	160/200	2.69E-28	5.01E-25
Restless_legs_syndrome_susceptibility_to_5	155/200	1.01E-24	1.25E-21
Shprintzen-Goldberg_craniosynostosis_syndrome	153/200	2.21E-23	1.65E-20
Fetal_brain_disruption_sequence	153/200	2.21E-23	1.65E-20
Peters_anomaly	152/200	9.95E-23	5.3E-20
Marfanoid_hypermobility_syndrome	152/200	9.95E-23	5.3E-20
Kosztolanyi_syndrome	151/200	4.35E-22	2.03E-19
Chromosome_2_monosomy_2q24	150/200	1.85E-21	6.28E-19
Acromesomelic_dysplasia_Hunter_Thompson_type	150/200	1.85E-21	6.28E-19
Acromesomelic_dysplasia	150/200	1.85E-21	6.28E-19
Chromosome_3_trisomy_3p	149/200	7.69E-21	2.2E-18
Buschke_Ollendorff_syndrome	149/200	7.69E-21	2.2E-18
Fraser_like_syndrome	148/200	3.11E-20	6.81E-18
Crandall_syndrome	148/200	3.11E-20	6.81E-18
Orofaciodigital_syndrome_11	148/200	3.11E-20	6.81E-18
Postaxial_polydactyly_mental_retardation	148/200	3.11E-20	6.81E-18
Short_rib-polydactyly_syndrome_type_4	147/200	1.22E-19	2.28E-17
Trichorhinophalangeal_syndrome_type_3	147/200	1.22E-19	2.28E-17
Duane_syndrome	147/200	1.22E-19	2.28E-17





Top 20 of 1,116 significant records

Term	Overlap	P-value	Adjusted P-value
Kallmann_syndrome	159/247	9.25E-13	5.25E-09
Apert_syndrome	145/219	2.58E-12	5.25E-09
Saethre-Chotzen_syndrome	136/206	2.62E-12	3.25E-09
Pitt_syndrome	241/410	4.01E-12	3.73E-09
Syndactyly_type_2	124/188	2.62E-11	1.95E-08
Polysyndactyly_cardiac_malformation	77/104	3.2E-11	1.98E-08
Syndactyly_type_1	122/185	3.85E-11	2.04E-08
Peters_anomaly	75/101	4.53E-11	2.1E-08
Cerebral_cavernous_malformation	157/252	5.65E-11	2.53E-08
Anophthalmia_or_microphthalmia_retinal_dystrophy_and/or_myopia_associated_with_brain_anomalies	182/301	6.82E-11	2.36E-08
X-linked_periventricular_heterotopia	89/126	6.98E-11	2.56E-08
Aniridia	171/282	1.85E-10	5.73E-08
Dominant_cleft_palate	163/267	2.37E-10	6.76E-08
Craniofacial_and_skeletal_defects	94/137	2.64E-10	7.01E-08
Anodontia	140/223	2.84E-10	7.03E-08
Glaucoma_congenital	202/345	3.48E-10	8.08E-08
Childhood-Onset_Schizophrenia	168/278	3.87E-10	8.46E-08
Hennekam_syndrome	139/223	6.68E-10	1.38E-07
Kurczynski_Casperson_syndrome	114/176	8.57E-10	1.68E-07
Osteochondroma	177/299	1.31E-09	2.44E-07



Figure 6. Identification of genes implicated in more than 1,000 records classified as human rare diseases.







GO Biological Process (8,045 genes): Top 35 of 308 significant records

Term	Overlap	P-value	Adjusted P-value
positive regulation of transcription from RNA polymerase II promoter (GO:0045944)	485/849	1.12E-19	5.67E-16
regulation of transcription from RNA polymerase II promoter (GO:0006357)	786/1479	2.51E-19	6.37E-16
positive regulation of transcription, DNA-templated (GO:0045893)	611/1121	3.46E-18	5.85E-15
nervous system development (GO:0007399)	276/456	7.07E-16	8.98E-13
regulation of apoptotic process (GO:0042981)	453/816	1.74E-15	1.77E-12
neuron differentiation (GO:0030182)	100/140	1.57E-12	1.33E-09
axonogenesis (GO:0007409)	146/224	1.88E-12	1.37E-09
negative regulation of apoptotic process (GO:0043066)	279/486	3.63E-12	2.31E-09
negative regulation of transcription, DNA-templated (GO:0045892)	437/814	5.48E-12	3.07E-09
generation of neurons (GO:0048699)	93/131	1.66E-11	7.69E-09
regulation of cell proliferation (GO:0042127)	400/741	1.67E-11	7.69E-09
positive regulation of nucleic acid-templated transcription (GO:1903508)	284/503	2.98E-11	1.26E-08
negative regulation of transcription from RNA polymerase II promoter (GO:0000122)	314/566	4.51E-11	1.76E-08
regulation of cell migration (GO:0030334)	190/317	7.61E-11	2.76E-08
positive regulation of gene expression (GO:0010628)	410/772	1.69E-10	5.73E-08
axon guidance (GO:0007411)	106/159	2.78E-10	8.82E-08
negative regulation of cellular process (GO:0048523)	295/535	4.21E-10	1.26E-07
negative regulation of cell proliferation (GO:0008285)	210/364	9.35E-10	2.64E-07
negative regulation of programmed cell death (GO:0043069)	232/409	1.08E-09	2.88E-07
protein phosphorylation (GO:0006468)	261/471	2.26E-09	5.62E-07
negative regulation of gene expression (GO:0010629)	332/619	2.32E-09	5.62E-07
positive regulation of macromolecule metabolic process (GO:0010604)	165/277	2.5E-09	5.78E-07
transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169)	224/397	3.91E-09	8.63E-07
positive regulation of cell differentiation (GO:0045597)	122/195	5.25E-09	1.11E-06
activation of protein kinase activity (GO:0032147)	142/234	5.85E-09	1.19E-06
positive regulation of protein phosphorylation (GO:0001934)	231/413	6.36E-09	1.24E-06
central nervous system development (GO:0007417)	133/218	1.1E-08	2.06E-06
negative regulation of cellular macromolecule biosynthetic process (GO:2000113)	278/513	1.29E-08	2.34E-06
regulation of transcription, DNA-templated (GO:0006355)	776/1599	2.65E-08	4.64E-06
positive regulation of epithelial cell migration (GO:0010634)	55/75	3.67E-08	6.13E-06
cellular protein modification process (GO:0006464)	504/1002	3.74E-08	6.13E-06
positive regulation of cell migration (GO:0030335)	133/222	5.27E-08	8.35E-06
positive regulation of cell proliferation (GO:0008284)	233/425	5.42E-08	8.35E-06
neuron projection morphogenesis (GO:0048812)	103/164	5.98E-08	8.94E-06
positive regulation of multicellular organismal process (GO:0051240)	123/203	6.72E-08	9.66E-06

GO Molecular Function (8,045 genes): Top 30 of 81 significant records

Term	Overlap	P-value	Adjusted P-value
cadherin binding (GO:0045296)	191/314	1.1E-11	1.26E-08
transcription regulatory region DNA binding (GO:0044212)	216/375	6.56E-10	3.76E-07
transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding (GO:0000982)	168/281	1.22E-09	4.66E-07
RNA polymerase II transcription factor binding (GO:0001085)	84/122	1.79E-09	5.11E-07
transcription regulatory region sequence-specific DNA binding (GO:0000976)	171/293	1.06E-08	2.43E-06
transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding (GO:0001228)	166/285	2.1E-08	4.01E-06
protein kinase binding (GO:0019901)	268/496	3.35E-08	5.4E-06
RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977)	251/461	3.78E-08	5.4E-06
protein kinase activity (GO:0004672)	276/514	4.5E-08	5.72E-06
transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding (GO:0001077)	109/176	7.35E-08	8.4E-06
GTPase regulator activity (GO:0030695)	154/276	2.44E-06	0.000254
amyloid-beta binding (GO:0001540)	37/50	4.47E-06	0.000426
protein serine/threonine kinase activity (GO:0004674)	197/369	5.99E-06	0.000518
repressing transcription factor binding (GO:0070491)	39/54	6.67E-06	0.000518
RNA polymerase II regulatory region DNA binding (GO:0001012)	116/202	6.8E-06	0.000518
GTPase activator activity (GO:0005096)	139/250	9.43E-06	0.000675
voltage-gated cation channel activity (GO:0022843)	64/101	1.2E-05	0.000807
motor activity (GO:0003774)	56/86	1.28E-05	0.000811
regulatory region DNA binding (GO:0000975)	126/225	1.52E-05	0.000916
core promoter proximal region sequence-specific DNA binding (GO:0000987)	152/279	1.65E-05	0.000943
protein homodimerization activity (GO:0042803)	332/665	1.79E-05	0.000973
actin binding (GO:0003779)	140/255	2.09E-05	0.001086
PDZ domain binding (GO:0030165)	43/63	2.29E-05	0.001141
RNA polymerase II core promoter proximal region sequence-specific DNA binding (GO:0000978)	143/263	3.29E-05	0.001569
transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding (GO:0001227)	92/160	5.43E-05	0.002452
protein tyrosine kinase activity (GO:0004713)	86/148	5.57E-05	0.002452
microtubule motor activity (GO:0003777)	41/61	6.16E-05	0.002608
tubulin binding (GO:0015631)	138/256	7.7E-05	0.003145
microtubule binding (GO:0008017)	109/196	8.13E-05	0.003208
acetylgalactosaminyltransferase activity (GO:0008376)	34/49	9.81E-05	0.003742



GO Cellular Component (8,045 genes): 29 significant records

Term	Overlap	P-value	Adjusted P-value
cytoskeleton (GO:0005856)	284/521	4.18E-09	1.85E-06
dendrite (GO:0030425)	131/216	2.35E-08	5.12E-06
axon (GO:0030424)	92/142	3.47E-08	5.12E-06
actin cytoskeleton (GO:0015629)	169/295	7.67E-08	8.23E-06
integral component of plasma membrane (GO:0005887)	711/1464	9.29E-08	8.23E-06
focal adhesion (GO:0005925)	194/357	1.52E-06	0.000112
Golgi subcompartment (GO:0098791)	250/480	4.46E-06	0.000282
perinuclear region of cytoplasm (GO:0048471)	198/379	3.32E-05	0.001839
cytoplasmic vesicle membrane (GO:0030659)	38/55	4.48E-05	0.002203
Golgi membrane (GO:0000139)	225/443	0.000104	0.004546
cortical cytoskeleton (GO:0030863)	36/53	0.000123	0.004546
cortical actin cytoskeleton (GO:0030864)	36/53	0.000123	0.004546
caveola (GO:0005901)	38/57	0.000148	0.00505
filopodium (GO:0030175)	40/61	0.000173	0.005461
membrane raft (GO:0045121)	70/120	0.000224	0.006622
endoplasmic reticulum lumen (GO:0005788)	142/271	0.000339	0.009382
microtubule organizing center (GO:0005815)	251/508	0.000401	0.010456
cytoplasmic vesicle (GO:0031410)	115/216	0.000546	0.013065
chromatin (GO:0000785)	153/297	0.00056	0.013065
nuclear chromatin (GO:0000790)	132/254	0.000826	0.018285
catenin complex (GO:0016342)	21/29	0.0009	0.018978
ionotropic glutamate receptor complex (GO:0008328)	27/40	0.001001	0.020165
dendrite membrane (GO:0032590)	16/21	0.001571	0.030261
cation channel complex (GO:0034703)	40/66	0.00177	0.032667
centrosome (GO:0005813)	225/462	0.00199	0.035259
main axon (GO:0044304)	23/34	0.002257	0.038461
junctional sarcoplasmic reticulum membrane (GO:0014701)	10-Sep	0.002537	0.040494
microtubule cytoskeleton (GO:0015630)	191/389	0.002642	0.040494
actin-based cell projection (GO:0098858)	42/71	0.002651	0.040494
ruffle membrane (GO:0032587)	33/54	0.003598	0.053124

Figure 7. Gene ontology analyses of putative regulatory targets of genetic loci harboring human-specific SNCs.



KEGG 2019 Human (8,405 genes): Top 40 of 129 significant records

Term	Overlap	P-value	Adjusted P-value
Pathways in cancer	512/550	2.04E-15	6.28E-13
Calcium signaling pathway	130/188	4.19E-14	6.45E-12
Proteoglycans in cancer	136/201	1.55E-13	1.59E-11
Hippo signaling pathway	112/160	6.61E-13	5.09E-11
cAMP signaling pathway	140/212	1.21E-12	7.48E-11
Rap1 signaling pathway	133/206	4.85E-11	2.49E-09
MAPK signaling pathway	179/295	6.48E-11	2.85E-09
Gastric acid secretion	59/75	9.75E-11	3.75E-09
Axon guidance	118/181	2.39E-10	8.17E-09
Aldosterone synthesis and secretion	71/98	9.54E-10	2.94E-08
cGMP-PKG signaling pathway	108/166	1.62E-09	4.54E-08
Focal adhesion	125/199	2.39E-09	6.14E-08
AGE-RAGE signaling pathway in diabetic complications	70/100	1.35E-08	3.13E-07
Dopaminergic synapse	87/131	1.42E-08	3.13E-07
Signaling pathways regulating pluripotency of stem cells	91/139	1.94E-08	3.98E-07
Wnt signaling pathway	101/158	2.15E-08	4.13E-07
Adrenergic signaling in cardiomyocytes	94/145	2.36E-08	4.28E-07
Gastric cancer	96/149	2.67E-08	4.56E-07
Amoebiasis	67/96	3.33E-08	5.32E-07
Thyroid hormone signaling pathway	78/116	3.45E-08	5.32E-07
PI3K-Akt signaling pathway	199/354	4.17E-08	6.11E-07
Long-term potentiation	50/67	5.95E-08	8.32E-07
Melanogenesis	69/101	8.04E-08	1.08E-06
Breast cancer	93/147	1.57E-07	2.02E-06
Insulin secretion	60/86	1.75E-07	2.16E-06
Cushing syndrome	97/155	1.84E-07	2.18E-06
Circadian entrainment	66/97	1.94E-07	2.22E-06
Glutamatergic synapse	75/114	2.48E-07	2.73E-06
Mucin type O-glycan biosynthesis	27/31	2.65E-07	2.81E-06
Relaxin signaling pathway	83/130	4.06E-07	4.17E-06
GnRH signaling pathway	65/95	4.68E-07	4.65E-06
Cholinergic synapse	73/112	6.18E-07	5.95E-06
Oxytocin signaling pathway	94/153	9.5E-07	8.87E-06
Inflammatory mediator regulation of TRP channels	66/100	1.08E-06	9.78E-06
Small cell lung cancer	62/93	1.35E-06	1.19E-05
Human papillomavirus infection	181/350	1.53E-06	1.31E-05
Neuroactive ligand-receptor interaction	184/358	2.41E-06	2.01E-05
Colorectal cancer	57/86	4.72E-06	3.82E-05
Gap junction	58/88	5.1E-06	4.03E-05
TGF-beta signaling pathway	59/90	5.49E-06	4.22E-05

KEGG 2019 Mouse: 8,405 genes



KEGG 2019 Mouse (8,405 genes): Top 35 of 106 significant records

Term	Overlap	P-value	Adjusted P-value
Proteoglycans in cancer	136/203	4.94E-13	1.5E-10
Calcium signaling pathway	127/189	2.09E-12	3.16E-10
cAMP signaling pathway	137/211	1.36E-11	1.38E-09
Pathways in cancer	300/535	2.41E-11	1.83E-09
Hippo signaling pathway	108/159	3.32E-11	2.01E-09
Axon guidance	119/180	5.22E-11	2.64E-09
MAPK signaling pathway	176/294	4.31E-10	1.86E-08
Rap1 signaling pathway	131/209	1.22E-09	4.62E-08
Focal adhesion	125/199	2.39E-09	8.05E-08
Gastric acid secretion	56/74	3.97E-09	1.2E-07
Signaling pathways regulating pluripotency of stem cells	90/137	1.8E-08	4.96E-07
Thyroid hormone signaling pathway	77/115	5.58E-08	1.41E-06
AGE-RAGE signaling pathway in diabetic complications	69/101	8.04E-08	1.88E-06
cGMP-PKG signaling pathway	106/172	1.58E-07	3.43E-06
Gastric cancer	94/150	2.59E-07	5.22E-06
Breast cancer	92/147	3.76E-07	7.12E-06
Aldosterone synthesis and secretion	68/102	4.22E-07	7.52E-06
Insulin secretion	59/86	5.53E-07	9.32E-06
Glutamatergic synapse	74/114	6.6E-07	1.05E-05
Long-term potentiation	48/67	8.6E-07	1.3E-05
Melanogenesis	66/100	1.08E-06	1.56E-05
Adrenergic signaling in cardiomyocytes	91/148	1.34E-06	1.84E-05
PI3K-Akt signaling pathway	194/357	1.52E-06	1.98E-05
Relaxin signaling pathway	82/131	1.57E-06	1.98E-05
Dopaminergic synapse	84/135	1.68E-06	2.04E-05
GnRH signaling pathway	60/90	1.99E-06	2.32E-05
Small cell lung cancer	61/92	2.17E-06	2.43E-05
Mucin type O-glycan biosynthesis	24/28	2.36E-06	2.56E-05
Cholinergic synapse	72/113	2.6E-06	2.72E-05
Wnt signaling pathway	96/160	3.27E-06	3.3E-05
ErbB signaling pathway	56/84	4.34E-06	4.24E-05
Circadian entrainment	64/99	4.53E-06	4.29E-05
Oxytocin signaling pathway	92/154	6.68E-06	6.13E-05
Cushing syndrome	94/159	9.8E-06	8.74E-05
Gap junction	56/86	1.28E-05	0.000111

Figure 8. KEGG analyses of putative regulatory targets of genetic loci harboring human-specific SNCs.

Association with networks of human-specific regulatory sequences (HSGRS) and stem cell-associated retroviral sequences (SCARS) of 8,405 genes associated with 35,074 fixed human-specific single nucleotide changes located in differentially-accessible chromatin regions during human neurogenesis in cerebral organoids

Classification category	Number of genes	Perent
Unique genes	8405	100.00
In network of human-specific genomic regulatory sequences (HSGRS)	7406	88.11
LTR5_Hs/SVA_D enhancers-regulated genes	1387	16.50
HERVH lncRNA-regulated genes	3191	37.97
LTR7Y/B enhancers-regulated genes	3306	39.33
In network of stem cell-associated retroviral sequences (SCARS)	4029	47.94
Both HSRGS & SCARS-regulated genes	3602	42.86
All HSGRS & SCARS-regulated genes	7833	93.19



Effects of stem cell-associated regulatory sequences (SCARS) on expression of 4,029 genes associated with human-specific SNCs located in DA chromatin regions

Classification category	Number of genes	Down-regulated	Percent	Up-regulated	Percent
LTR5_Hs/SVA_D enhancers-regulated genes	1387	1210	87.24	177	12.76
HERVH lncRNA-regulated genes	3191	1733	54.31	1458	45.69
LTR7Y/B enhancers-regulated genes	3306	2494	75.44	812	24.56

Figure 9. Structurally, functionally, and evolutionary distinct classes of HSRS share the relatively restricted elite set of common genetic targets.





MGI Mammalian Phenotype 2017 (8,405 genes): Top 40 of 749 significant records

Term	Overlap	P-value	Adjusted P-value
MP:0001262_decreased_body_weight	692/1189	4.71E-51	2.44E-27
MP:0001265_decreased_body_size	472/774	2.25E-27	5.82E-24
MP:0011087_neonatal_lethality,_complete_penetrance	299/462	2.47E-23	4.25E-20
MP:0011086_postnatal_lethality,_incomplete_penetrance	346/563	4.06E-21	5.26E-18
MP:0002169_no_abnormal_phenotype_detected	882/1674	2.98E-20	3.08E-17
MP:0002083_premature_death	474/834	1.12E-18	9.65E-16
MP:0001405_impaired_coordination	215/332	5.43E-17	2.54E-14
MP:0011085_postnatal_lethality,_complete_penetrance	258/384	1.57E-15	1.02E-12
MP:0001399_hyperactivity	216/344	4.36E-15	2.51E-12
MP:0011090_perinatal_lethality,_incomplete_penetrance	152/226	1.28E-14	6.65E-12
MP:0001732_postnatal_growth_retardation	339/590	1.43E-14	6.75E-12
MP:0001463_abnormal_spatial_learning	115/162	6.87E-14	2.96E-11
MP:0011091_prenatal_lethality,_complete_penetrance	174/272	1.81E-13	7.22E-11
MP:0011098_embryonic_lethality_during_organogenesis,_complete_penetrance	319/559	2.9E-13	1.07E-10
MP:0011088_neonatal_lethality,_incomplete_penetrance	163/255	1.15E-12	3.97E-10
MP:0001698_decreased_embryo_size	273/472	1.96E-12	6.36E-10
MP:0000267_abnormal_heart_development	109/157	3.11E-12	9.48E-10
MP:0011109_lethality_throughout_fetal_growth_and_development,_incomplete_penetrance	116/170	5.92E-12	1.13E-09
MP:0002152_abnormal_brain_morphology	104/152	3.9E-11	1.06E-08
MP:0011110_preweaning_lethality,_incomplete_penetrance	222/381	8.85E-11	2.29E-08
MP:0001473_reduced_long_term_potentiation	77/106	1.52E-10	3.75E-08
MP:0001923_reduced_female_fertility	142/227	3.06E-10	7.2E-08
MP:0004811_abnormal_neuron_physiology	67/90	4.06E-10	8.85E-08
MP:0000788_abnormal_cerebral_cortex_morphology	98/145	4.1E-10	8.85E-08
MP:0001406_abnormal_gait	180/302	4.48E-10	9.28E-08
MP:0001469_abnormal_contextual_conditioning_behavior	45/54	4.96E-10	9.82E-08
MP:0000849_abnormal_cerebellum_morphology	68/92	5.12E-10	9.82E-08
MP:0000266_abnormal_heart_morphology	159/224	1.03E-09	1.91E-07
MP:0000852_small_cerebellum	52/66	1.15E-09	2.05E-07
MP:0001953_respiratory_failure	98/147	1.29E-09	2.23E-07
MP:0011089_perinatal_lethality,_complete_penetrance	135/217	1.41E-09	2.35E-07
MP:0002206_abnormal_CNS_synaptic_transmission	66/90	1.6E-09	2.59E-07
MP:0000438_abnormal_cranium_morphology	90/133	1.91E-09	2.99E-07
MP:0001302_eyelids_open_at_birth	43/52	1.97E-09	3E-07
MP:0000807_abnormal_hippocampus_morphology	63/86	4.04E-09	5.97E-07
MP:0006009_abnormal_neuronal_migration	57/76	5.14E-09	7.28E-07
MP:0001954_respiratory_distress	111/174	5.2E-09	7.28E-07
MP:0001899_absent_long_term_depression	25/26	5.88E-09	7.95E-07
MP:0002906_increased_susceptibility_to_pharmacologically_induced_seizures	65/90	5.99E-09	7.95E-07
MP:0003633_abnormal_nervous_system_physiology	74/106	6.53E-09	8.12E-07

MGI Mammalian Phenotype Level 4 2019: 8.405 genes





MGI Mammalian Phenotype Level 4 2019 (8,405 genes): top 40 of 407 significant records

Term	Overlap	P-value	Adjusted P-value
MP:0011087_neonatal_lethality,_complete_penetrance	315/517	1.55E-18	8.15E-15
MP:0001262_decreased_body_weight	773/1471	2.04E-17	5.36E-14
MP:0001405_impaired_coordination	247/405	6.90E-15	1.21E-11
MP:0011086_postnatal_lethality,_incomplete_penetrance	362/643	9.65E-14	1.27E-10
MP:0001463_abnormal_spatial_learning	120/172	1.46E-13	1.54E-10
MP:0002169_no_abnormal_phenotype_detected	958/1944	6.87E-12	6.02E-09
MP:0004811_abnormal_neuron_physiology	78/107	8.69E-11	6.55E-08
MP:0002206_abnormal_CNS_synaptic_transmission	75/103	2.18E-10	1.27E-07
MP:0000267_abnormal_heart_development	111/168	2.43E-10	1.28E-07
MP:0011085_postnatal_lethality,_complete_penetrance	246/432	2.04E-10	1.34E-07
MP:0011110_preweaning_lethality,_incomplete_penetrance	360/669	2.90E-10	1.39E-07
MP:0011109_lethality_throughout_fetal_growth_and_development,_incomplete_penetrance	122/191	8.21E-10	3.60E-07
MP:0001899_absent_long_term_depression	27/28	1.11E-09	4.50E-07
MP:0001732_postnatal_growth_retardation	360/677	1.85E-09	6.48E-07
MP:0001698_decreased_embryo_size	293/537	2.09E-09	6.88E-07
MP:0002152_abnormal_brain_morphology	119/187	1.84E-09	6.92E-07
MP:0011090_perinatal_lethality,_incomplete_penetrance	154/256	3.25E-09	9.44E-07
MP:0002741_small_olfactory_bulb	35/40	3.07E-09	9.51E-07
MP:0001469_abnormal_contextual_conditioning_behavior	48/61	5.45E-09	1.43E-06
MP:0001475_reduced_long_term_potentiation	84/124	6.05E-09	1.45E-06
MP:0000788_abnormal_cerebral_cortex_morphology	104/161	5.79E-09	1.45E-06
MP:0011088_neonatal_lethality,_incomplete_penetrance	172/293	5.38E-09	1.48E-06
MP:0001954_respiratory_distress	121/194	7.90E-09	1.81E-06
MP:0001575_cyanosis	129/210	1.00E-08	2.19E-06
MP:0001953_respiratory_failure	103/161	1.47E-08	3.09E-06
MP:0002906_increased_susceptibility_to_pharmacologically_induced_seizures	70/101	2.60E-08	5.25E-06
MP:0002910_abnormal_excitatory_postsynaptic_currents	59/83	7.68E-08	1.50E-05
MP:0002083_premature_death	499/997	9.80E-08	1.84E-05
MP:0002066_abnormal_motor_capabilities/coordination/movement	102/164	1.41E-07	2.55E-05
MP:0006254_thin_cerebral_cortex	53/74	2.36E-07	4.14E-05
MP:0011098_embryonic_lethality_during_organogenesis,_complete_penetrance	339/656	2.60E-07	4.28E-05
MP:0000807_abnormal_hippocampus_morphology	65/92	2.56E-07	4.34E-05
MP:0005009_abnormal_neuronal_migration	59/85	2.94E-07	4.69E-05
MP:0011108_embryonic_lethality_during_organogenesis,_incomplete_penetrance	143/247	3.20E-07	4.95E-05
MP:0000031_abnormal_cochlea_morphology	44/59	3.84E-07	5.77E-05
MP:0000852_small_cerebellum	58/84	4.91E-07	7.17E-05
MP:0002063_abnormal_learning/memory/conditioning	42/56	5.43E-07	7.52E-05
MP:0003633_abnormal_nervous_system_physiology	79/123	5.36E-07	7.62E-05
MP:0010025_decreased_total_body_fat_amount	263/498	5.94E-07	8.01E-05
MP:0009937_abnormal_neuron_differentiation	75/116	7.01E-07	9.22E-05

Figure 10. Interrogation of MGI Mammalian Phenotype databases identifies genes associated with human-specific SNCs and implicated in premature death and embryonic, perinatal, neonatal, and postnatal lethality phenotypes.





Figure 11. Identification of 2,273 genes (offspring survival genes) associated with human-specific SNCs and implicated in premature death and embryonic, perinatal, neonatal, and postnatal lethality phenotypes. Bottom figure shows identification of offspring survival genes that were implicated in the autosomal dominant (389 genes) and recessive (426 genes) inheritance in Modern Humans.